NON RARE IN EUROPE: Eosinophilic esophagitis

Advocacy intelligence hub — real-time data for patient organizations

View full disease page →Search clinical trials →

At a Glance

Live from database

2FDA treatments

18Recruiting trials

Regulatory Watchboard

10 events

Apr 2026

DUPIXENT: New indication approved

FDAcompleted

Apr 2026DUPIXENT: New indication approved

FDAcompleted

Feb 2026DUPIXENT: New indication approved

FDAcompleted

Feb 2026Comparison of Eohilia With Dupixent on Esophagus Diameter in Patients With Eosinophilic Esophagitis.

Mayo Clinic — EARLY_PHASE1

TrialNOT YET RECRUITING

Dec 2025Trial of Partial Enteral Nutrition With Dairy Free Diet in Eosinophilic Esophagitis

Kate Farms Inc — NA

TrialNOT YET RECRUITING

Nov 2025A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic Esophagitis

Regeneron Pharmaceuticals — PHASE3

TrialRECRUITING

Aug 2025Surface EMG Testing on Swallowing in EoE Patients

Mayo Clinic

TrialRECRUITING

Aug 2025Trans-Cervical and Trans-abdominal Ultrasound for Monitoring Esophageal Thickness in Eosinophilic Esophagitis

Sheba Medical Center — NA

TrialNOT YET RECRUITING

Jul 2025Prevalence and Description of FIRE (Food Induced Immediate Response of the Esophagus) in the Pediatric Population With Eosinophilic Esophagitis

University Hospital, Angers

TrialRECRUITING

Jul 2025Local Clinical and Immunological Responses in Eosinophilic Esophagitis (EoE) Patients, Role of Mucosal Barrier Function and Type II Inflammation

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

TrialRECRUITING

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

2 programs

FINANCIAL LANDSCAPE SUMMARY

2

Total programs

2

Open now

Patient Assistance Programs2

Dupixent

Regeneron Pharmaceuticals, Inc.

OpenContact for detailsApply ↗

Eohilia

Takeda Pharmaceuticals U.S.A., Inc.

OpenContact for detailsApply ↗

View all support programs on disease page →

Approved Treatments

2 FDA-approved

Eohilia

(budesonide)Orphan drug

Takeda Pharmaceuticals U.S.A., Inc.

Corticosteroid [EPC]

12.1 Mechanism of Action Budesonide is an anti-inflammatory corticosteroid and has a high glucocorticoid effect and a weak mineralocorticoid effect, a...

Approved Feb 2024FDA label ↗

Dupixent

(dupilumab)Orphan drug

Regeneron Pharmaceuticals, Inc.

Interleukin-4 Receptor alpha Antagonist [EPC]

12.1 Mechanism of Action Dupilumab is a human monoclonal IgG4 antibody that inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling by spec...

Approved May 2022FDA label ↗

View full treatment details on disease page →

Clinical Trial Landscape

18 active trials

1Phase 3

2Phase 4

3Phase 2

3N/A

9Unknown

18Total recruiting

Search clinical trials for NON RARE IN EUROPE: Eosinophilic esophagitis →

Recent News & Research

No recent news articles indexed yet for NON RARE IN EUROPE: Eosinophilic esophagitis.
Search PubMed for NON RARE IN EUROPE: Eosinophilic esophagitis →

Browse all NON RARE IN EUROPE: Eosinophilic esophagitis news →

Specialist Network

No specialists currently listed for NON RARE IN EUROPE: Eosinophilic esophagitis.

View all NON RARE IN EUROPE: Eosinophilic esophagitis specialists →

Quick Actions

View Disease Page

Full profile, treatments, community

Search Clinical Trials

Find recruiting studies now

Find Specialists

Ranked by expertise & trials

Financial Assistance

Copay cards, PAPs, grants

Latest News

Research, approvals & updates

Browse All Diseases

11,000+ rare disease profiles